Affera, a Medtronic company, is focused on developing innovative medical technologies for the treatment of cardiac arrhythmias. The company is creating a comprehensive integrated platform designed to provide durable therapy for a wide range of patients suffering from these conditions. Among its notable advancements is the development of a lattice-tip focal ablation catheter that can toggle between radiofrequency and pulsed field energy, specifically aimed at treating atrial fibrillation. This technology is part of a broader effort to enhance the safety and efficacy of cardiac ablation procedures, which are critical for managing arrhythmias.

The company has also made significant strides in pulsed field ablation (PFA) techniques, which are being evaluated for their feasibility and safety in various clinical settings. Publications highlight preclinical assessments and first-in-human trials that demonstrate the potential of PFA for pulmonary vein isolation and other cardiac applications. Affera's commitment to research and innovation is evident in its active participation in scientific discussions and trials, showcasing its technologies at major medical conferences and contributing to the evolving landscape of cardiac arrhythmia treatment.

United States

Affera is a venture-backed medical device company founded by a seasoned team of leaders in the industry. We are developing an innovative system to treat heart rhythm disorders, a prevalent condition affecting millions of patients worldwide.

Follow us as we share updates about our progress.

Affera

Company Details